Fitzhugh, C. D., Cordes, S., Taylor, T., Coles, W., Roskom, K., Link, M., . . . Tisdale, J. F. (2017). At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT. Blood.

Fitzhugh, Courtney D., Stefan Cordes, Tiffani Taylor, Wynona Coles, Katherine Roskom, Mary Link, Matthew M. Hsieh, and John F. Tisdale. "At Least 20% Donor Myeloid Chimerism Is Necessary to Reverse the Sickle Phenotype After Allogeneic HSCT." Blood 2017.

Fitzhugh, Courtney D., et al. "At Least 20% Donor Myeloid Chimerism Is Necessary to Reverse the Sickle Phenotype After Allogeneic HSCT." Blood 2017.